Sanofi Closes In On A Pair Of Approval Firsts
Dupixent Approvals Expanded As Xenpozyme Gets CHMP Nod
The French major has secured a fourth approval, in eosinophilic esophagitis, for Dupixent, while the EMA is set to make Sanofi's enzyme replacement therapy, Xenpozyme, the first drug approved in Europe for acid sphingomyelinase deficiency.
